Skip to main content

Catalyst Calendar

Scope

Tue, Aug 25, 2026

1 updates
NKTR
8:30 AM

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

REZOLVE-AD study met all primary and key secondary endpoints, including EASI -75, EASI -90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease

Trial Results • Phase 2nektar.com

Thu, Aug 13, 2026

1 updates
NKTR
4:15 PM

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities

Presentation / Abstract • Phase 2EADV oral presentation Thu, Oct 1, 2026, 10:25 AM CESTnektar.com

Tue, Jul 28, 2026

1 updates

Fri, Jul 24, 2026

1 updates

Tue, Jul 21, 2026

1 updates
NKTR
7:00 AM

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in EASI -100

Trial Start • Phase 3Trial initiation Tue, Jul 21, 2026nektar.com

Fri, Jun 26, 2026

1 updates

Wed, Jun 3, 2026

1 updates